[1] Burki T. WHO′s 2024 global hepatitis report[J]. Lancet Infect Dis, 2024, 24(6):2.
[2] Jeng W J, Papatheodoridis G V, Lok A S F. Hepatitis B[J]. Lancet, 2023, 401(10381):1039-1052.
[3] Halioua B, Skayem C, Merhand S, et al. Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis[J]. Br J Dermatol, 2024, 191(3):454-456.
[4] Natour R T, Midlej A, Mahajna E, et al. Chronic hepatitis B beyond clinical burden:psychosocial effects and impact on quality of life[J]. J Viral Hepat, 2024, 31(1):12-20.
[5] Wu B, Liu J, Shao C, et al. Integrating inflammation, nutrition, and immunity:the CALLY index as a prognostic tool in digestive system cancers—A systematic review and meta-analysis[J]. BMC Cancer, 2025, 25(1):672.
[6] Kang W, Zhao H, Lian Q, et al. Prognostic prediction and risk stratification of transarterial chemoembolization combined with targeted therapy and immunotherapy for unresectable hepatocellular carcinoma:a dual-center study[J]. J Hepatocell Carcinoma, 2024, 11:2169-2179.
[7] Iida H, Tani M, Komeda K, et al. Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma[J]. HPB (Oxford), 2022, 24(1):101-115.
[8] Han X, He L, Li S, et al. Trends in liver cancer rehabilitation needs, disease burden, and attributable risk factors in China, 1990-2021[J]. Sci Rep, 2025, 15(1):15682.
[9] Choi W J, Ivanics T, Claasen M, et al. Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection:a multicenter international study[J]. Surgery, 2025, 183:109396.
[10] Kawashima J, Endo Y, Khalil M, et al. Impact of anatomical resection on non-transplantable recurrence among patients with hepatocellular carcinoma:an international multicenter inverse probability of treatment weighting analysis[J]. Ann Surg Oncol, 2025, 32(9):6243-6253.
[11] Dirim M G, Cifcibasi Ormeci A, Cavus B, et al. Inflammation and immune-based scores predict prognosis for patients with hepatocellular carcinoma:a pilot single-center study[J]. Turk J Gastroenterol, 2025, 36(4):219-228.
[12] Yasuda S, Matsuo Y, Doi S, et al. Preoperative predictors of very early recurrence in patients with hepatocellular carcinoma beyond the Milan criteria[J]. Langenbecks Arch Surg, 2024, 409(1):283.
[13] Furukawa K, Tsunematsu M, Tanji Y, et al. Impact of C-reactive protein-albumin-lymphocyte (CALLY) index on prognosis after hepatectomy for colorectal liver metastasis[J]. Surg Oncol, 2023, 47:101911.
[14] Lang S Q, Kong J J, Li G B, et al. Prognostic value of CRP-albumin-lymphocyte index in patients with intrahepatic cholangiocarcinoma after radical resection[J]. Front Med, 2025, 12:1543665.
[15] Müller L, Hahn F, Mähringer-Kunz A, et al. Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolization:evaluation of the CALLY index[J]. Cancers (Basel), 2021, 13(19):5018.
[16] Chen D, Ma Y, Li J, et al. Prognostic and clinicopathological significance of C-reactive protein-albumin-lymphocyte (CALLY) in patients with digestive system neoplasms:a systematic review and meta-analysis[J]. World J Surg Oncol, 2025, 23(1):114.
[17] Zhu D, Lin Y D, Yao Y Z, et al. Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer:results from NHANES 1999-2018[J]. BMC Cancer, 2024, 24(1):1499.
[18] Radkhah H, Zooravar D, Shateri-Amiri B, et al. Predictive value of complete blood count (CBC)-derived indices—C-reactive-protein-albumin-lymphocyte index (CALLY), glucose-to-lymphocyte ratio (GLR), prognostic nutritional index (PNI), hemoglobin, albumin, lymphocyte, platelet (HALP), and controlling nutritional status (COUNT)—on body composition changes after bariatric surgery[J]. Obes Surg, 2025, 35(2):544-555.
[19] Chalasani N P, Maddur H, Russo M W, et al. ACG clinical guideline:diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5):878-898.
[20] Bessone F, Hernandez N, Tagle M, et al. Drug-induced liver injury:a management position paper from the Latin American Association for Study of the liver[J]. Ann Hepatol, 2021, 24:100321.
[21] Hirschfield G M, Chazouillères O, Cortez-Pinto H, et al. A consensus integrated care pathway for patients with primary biliary cholangitis:a guideline-based approach to clinical care of patients[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(8):929-939.
[22] Wiegang S B, Paal M, Jung J, et al. Importance of the neutrophil-to-lymphocyte ratio as a marker for microbiological specimens in critically ill patients after liver or lung transplantation[J]. Infection, 2025, 53(2):573-582.
[23] Fonseca A L F, Santos B C, Anastácio L R, et al. Global Leadership Initiative on Malnutrition criteria for the diagnosis of malnutrition and prediction of mortality in patients awaiting liver transplant:a validation study[J]. Nutrition, 2023, 114:112093.
[24] Yildiz G, Bedel C, Zortuk Ö, et al. CALLY index, but not HALP score, is associated with mortality in cirrhosis patients[J]. Rev Rom Med Lab, 2025, 33(1):29-34.
[25] Zhang J, Lin Y, Zeng J, et al. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index exhibits an L-shaped association with all-cause mortality in rheumatoid arthritis patients:a retrospective cohort study[J]. BMC Rheumatol, 2025, 9(1):47.
[26] Furukawa S, Hiraki M, Kimura N, et al. The potential of the C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in colorectal cancer[J]. Cancer Diagn Progn, 2025, 5(3):370-377.
[27] Lin X, Zhang L, Zheng Y, et al. A comprehensive prognosis model for adult septic shock:SOFAplusCALLY index[J]. Eur J Med Res, 2025, 30(1):111.
[28] Tsai Y T, Ko C A, Chen H C, et al. Prognostic value of CRP-albumin-lymphocyte (CALLY) index in patients undergoing surgery for oral cavity cancer[J]. J Cancer, 2022, 13(10):3000-3012. |
